NCT00868231 - Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Aclidinium bromide 400 μg bid

Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.

DRUG

Tiotropium 18 μg once-daily

Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.

DRUG

Placebo

Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.

Trial Locations (2)

Almirall Investigational Site #1, Berlin

Almirall Investigational Site #2, Großhansdorf